Mitsubishi Tanabe Pharma Corporation – Product Pipeline Review

Global Markets Direct’s, ‘Mitsubishi Tanabe Pharma Corporation – Product Pipeline Review – 2016’, provides an overview of the Mitsubishi Tanabe Pharma Corporation’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Mitsubishi Tanabe Pharma Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Mitsubishi Tanabe Pharma Corporation

The report provides overview of Mitsubishi Tanabe Pharma Corporation including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Mitsubishi Tanabe Pharma Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Mitsubishi Tanabe Pharma Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Mitsubishi Tanabe Pharma Corporation’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Mitsubishi Tanabe Pharma Corporation

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Mitsubishi Tanabe Pharma Corporation’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Mitsubishi Tanabe Pharma Corporation Snapshot 8

Mitsubishi Tanabe Pharma Corporation Overview 8

Key Facts 8

Mitsubishi Tanabe Pharma Corporation - Research and Development Overview 9

Key Therapeutic Areas 9

Mitsubishi Tanabe Pharma Corporation - Pipeline Review 13

Pipeline Products by Stage of Development 13

Pipeline Products - Monotherapy 14

Pipeline Products - Combination Treatment Modalities 15

Pipeline Products - Partnered Products 16

Partnered Products/Combination Treatment Modalities 17

Pipeline Products - Out-Licensed Products 18

Out-Licensed Products/Combination Treatment Modalities 19

Mitsubishi Tanabe Pharma Corporation - Pipeline Products Glance 20

Mitsubishi Tanabe Pharma Corporation - Late Stage Pipeline Products 20

Pre-Registration Products/Combination Treatment Modalities 20

Phase III Products/Combination Treatment Modalities 21

Mitsubishi Tanabe Pharma Corporation - Clinical Stage Pipeline Products 22

Phase II Products/Combination Treatment Modalities 22

Phase I Products/Combination Treatment Modalities 23

Mitsubishi Tanabe Pharma Corporation - Early Stage Pipeline Products 24

IND/CTA Filed Products/Combination Treatment Modalities 24

Preclinical Products/Combination Treatment Modalities 25

Discovery Products/Combination Treatment Modalities 26

Mitsubishi Tanabe Pharma Corporation - Drug Profiles 27

(canagliflozin + teneligliptin) - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

amiselimod hydrochloride - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

avanafil - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

bepotastine besylate - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

canagliflozin - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

cariprazine - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

edaravone - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

fingolimod hydrochloride - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

GB-1057 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

infliximab - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

masilukast - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

MIN-117 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Monoclonal Antibodies for Cancer - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Monoclonal Antibodies for Inflammatory Disorders - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Monoclonal Antibodies for Undisclosed Indication - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

MP-124 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

MP-157 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

MT-0814 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

MT-210 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

MT-3995 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

MT-4580 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

MT-7117 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

MT-8554 - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

NU-300 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Small Molecule to Inhibit S-Adenosyl-L-Homocysteine Hydrolase for Undisclosed Indication - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

Small Molecules to Block Sodium and hERG Channel for Ischemic Stroke - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

Small Molecules to Inhibit DPP-IV for Hyperglycemia - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Small Molecules to Inhibit GSK-3 Beta for Neurodegenerative Diseases - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

T-6932 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

TA-3404 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

teneligliptin - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

valbenazine tosylate - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

Y-320 - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Mitsubishi Tanabe Pharma Corporation - Pipeline Analysis 89

Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Target 89

Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Route of Administration 92

Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Molecule Type 93

Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Mechanism of Action 94

Mitsubishi Tanabe Pharma Corporation - Dormant Projects 97

Mitsubishi Tanabe Pharma Corporation - Discontinued Pipeline Products 99

Discontinued Pipeline Product Profiles 101

AMG-899 101

AV-412 101

caldaret 101

carmoterol 101

coleneuramide 101

colestilan chloride 101

ecabet 101

edaravone 102

encenicline hydrochloride 102

fingolimod hydrochloride 102

immune globulin (human) 102

marimastat 102

masilukast 103

MP-136 103

MP-435 103

MT-7716 103

netoglitazone 103

sofigatran 103

TA-5493 103

TA-5538 103

TA-6666 103

TAK-128 103

telaprevir 104

Y-700 104

Mitsubishi Tanabe Pharma Corporation - Company Statement 105

Mitsubishi Tanabe Pharma Corporation - Locations And Subsidiaries 106

Head Office 106

Other Locations & Subsidiaries 106

Appendix 110

Methodology 110

Coverage 110

Secondary Research 110

Primary Research 110

Expert Panel Validation 110

Contact Us 110

Disclaimer 111

List of Tables

List of Tables

Mitsubishi Tanabe Pharma Corporation, Key Facts 8

Mitsubishi Tanabe Pharma Corporation – Pipeline by Indication, 2016 11

Mitsubishi Tanabe Pharma Corporation – Pipeline by Stage of Development, 2016 13

Mitsubishi Tanabe Pharma Corporation – Monotherapy Products in Pipeline, 2016 14

Mitsubishi Tanabe Pharma Corporation – Combination Treatment Modalities in Pipeline, 2016 15

Mitsubishi Tanabe Pharma Corporation – Partnered Products in Pipeline, 2016 16

Mitsubishi Tanabe Pharma Corporation – Partnered Products/ Combination Treatment Modalities, 2016 17

Mitsubishi Tanabe Pharma Corporation – Out-Licensed Products in Pipeline, 2016 18

Mitsubishi Tanabe Pharma Corporation – Out-Licensed Products/ Combination Treatment Modalities, 2016 19

Mitsubishi Tanabe Pharma Corporation – Pre-Registration, 2016 20

Mitsubishi Tanabe Pharma Corporation – Phase III, 2016 21

Mitsubishi Tanabe Pharma Corporation – Phase II, 2016 22

Mitsubishi Tanabe Pharma Corporation – Phase I, 2016 23

Mitsubishi Tanabe Pharma Corporation – IND/CTA Filed, 2016 24

Mitsubishi Tanabe Pharma Corporation – Preclinical, 2016 25

Mitsubishi Tanabe Pharma Corporation – Discovery, 2016 26

Mitsubishi Tanabe Pharma Corporation – Pipeline by Target, 2016 90

Mitsubishi Tanabe Pharma Corporation – Pipeline by Route of Administration, 2016 92

Mitsubishi Tanabe Pharma Corporation – Pipeline by Molecule Type, 2016 93

Mitsubishi Tanabe Pharma Corporation – Pipeline Products by Mechanism of Action, 2016 95

Mitsubishi Tanabe Pharma Corporation – Dormant Developmental Projects,2016 97

Mitsubishi Tanabe Pharma Corporation – Discontinued Pipeline Products, 2016 99

Mitsubishi Tanabe Pharma Corporation, Other Locations 106

Mitsubishi Tanabe Pharma Corporation, Subsidiaries 107

List of Figures

List of Figures

Mitsubishi Tanabe Pharma Corporation – Pipeline by Top 10 Indication, 2016 10

Mitsubishi Tanabe Pharma Corporation – Pipeline by Stage of Development, 2016 13

Mitsubishi Tanabe Pharma Corporation – Monotherapy Products in Pipeline, 2016 14

Mitsubishi Tanabe Pharma Corporation – Partnered Products in Pipeline, 2016 16

Mitsubishi Tanabe Pharma Corporation – Out-Licensed Products in Pipeline, 2016 18

Mitsubishi Tanabe Pharma Corporation – Pipeline by Top 10 Target, 2016 89

Mitsubishi Tanabe Pharma Corporation – Pipeline by Route of Administration, 2016 92

Mitsubishi Tanabe Pharma Corporation – Pipeline by Molecule Type, 2016 93

Mitsubishi Tanabe Pharma Corporation – Pipeline Products by Top 10 Mechanism of Action, 2016 94

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports